Home    Contact Us    Send to Colleague    Search 

5 Jul 2016
arGentis receives U.S Patent for Arthritis Treatment
Memphis, TN—arGentis Pharmaceuticals, LLC announced today the issuance of EU patent No. 2,286,218 for a single nucleotide polymorphism (SNP) associated with resistance to immune tolerance. This SNP and will be used as a biomarker to identify patients that will respond to arGentis’ treatment for scleroderma.

The research supporting this patent was conducted at the University of Tennessee Health Science Center in Memphis, Tennessee and is licensed by arGentis™ from the University of Tennessee Research Foundation. This patent grants the use of this biomarker in the EU and is based upon the research of doctors Arnold Postlethwaite, Andrew Kang, and Weikuan Gu at the University of Tennessee Health Science Center in Memphis Tennessee.

Scleroderma is a complex and deadly autoimmune disease that attacks the naturally incurring type 1 collagen in the body. Collagen build up results in widespread connective tissue fibrosis and vascular injury leading to organ system failures. The arGentis treatment (ARG201) is targeted to treat diffuse systemic scleroderma (dSSc) which is the most serious type of Scleroderma and always leads to some internal organ involvement. It is a rare disease with a relative poor prognosis. Women are 4 to 5 times more likely than men to develop dSSc. Progressive pulmonary fibrosis, pulmonary hypertension, severe gastrointestinal involvement, and scleroderma heart disease are the main causes of death. Mortality rates are 5 to 8 times greater than the general population.

arGentis™ Pharmaceuticals, located in Tennessee was established in 2007 to develop pharmaceuticals that address unmet medical needs. The mission of arGentis™ is to develop and commercialize treatments to improve the health and quality of life of the targeted patient groups and provide a fair return to our investors.

The current focus is on autoimmune diseases treated primarily by Rheumatologists.

For more information, contact:
Tom Davis, President and CEO, arGentis Pharmaceuticals, LLC
901-881-8665

Return to Press Releases

© 2019 by Commercial Healthcare Partners. Website Design & Development by Birchwood Group   Commercial Healthcare Partners    Jim Usry